Tech Transfer Tidbits

Premium

Stanford Spinout Eiger Biopharma Licenses Hep C Drug Targets from School

Eiger Biopharmaceuticals, a recent spinout of Stanford University, said last week that it has licensed the exclusive rights to a hepatitis C virus technology from the university.

The technology, discovered in the laboratory of Stanford researcher and Eiger co-founder Jeffrey Glenn, pertains to a variety of drug targets, including key features of NS4B, a non-structural protein in the HCV genome that binds to HCV-RNA and is required for viral replication.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.